NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
NewAmsterdam Pharma (Nasdaq: NAMS) has announced it will report topline data from its Phase 3 BROOKLYN clinical trial (NCT05425745) on Monday, July 29, 2024. The trial evaluates obicetrapib in patients with heterozygous familial hypercholesterolemia. NewAmsterdam, a late-stage biopharmaceutical company, is developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The company will host a live webcast and conference call to review the results on July 29, 2024, at 8:30 a.m. ET. Participants can register for the webcast or telephone conference, and an archived replay will be available on the company's website.
NewAmsterdam Pharma (Nasdaq: NAMS) ha annunciato che presenterà i dati preliminari del suo studio clinico di fase 3 BROOKLYN (NCT05425745) lunedì 29 luglio 2024. Lo studio valuta l'obicetrapib in pazienti con ipercolesterolemia familiare eterozigote. NewAmsterdam, un'azienda biopharmaceutica in fase avanzata, sta sviluppando farmaci orali non statinici per pazienti a rischio di malattie cardiovascolari con livelli elevati di LDL-C. L'azienda ospiterà un webcast dal vivo e una conferenza telefonica per esaminare i risultati il 29 luglio 2024, alle 8:30 ET. I partecipanti possono registrarsi per il webcast o la conferenza telefonica, e una registrazione archiviata sarà disponibile sul sito web dell'azienda.
NewAmsterdam Pharma (Nasdaq: NAMS) ha anunciado que informará sobre los datos preliminares de su ensayo clínico de fase 3 BROOKLYN (NCT05425745) el lunes 29 de julio de 2024. El ensayo evalúa obicetrapib en pacientes con hipercolesterolemia familiar heterocigota. NewAmsterdam, una compañía biofarmacéutica en etapa avanzada, está desarrollando medicamentos orales no estatínicos para pacientes en riesgo de enfermedades cardiovasculares con niveles elevados de LDL-C. La compañía llevará a cabo un webcast en vivo y una conferencia telefónica para revisar los resultados el 29 de julio de 2024, a las 8:30 a.m. ET. Los participantes pueden registrarse para el webcast o la conferencia telefónica, y habrá una repetición archivada disponible en el sitio web de la compañía.
뉴암스테르담 제약(NewAmsterdam Pharma, Nasdaq: NAMS)은 3상 BROOKLYN 임상 시험의 주요 데이터 (NCT05425745)를 2024년 7월 29일 월요일에 발표할 것이라고 발표했습니다. 이 시험은 헤테로 접합형 가족성 고콜레스테롤혈증 환자에서 obicetrapib을 평가합니다. 뉴암스테르담은 심혈관 질환 위험이 있는 환자를 위해 비스타틴 경구 약물을 개발하고 있는 후기 단계의 생명공학 회사입니다. 이 회사는 2024년 7월 29일 오전 8시 30분 ET에 결과를 검토하기 위한 라이브 웹캐스트 및 전화 회의를 주최할 예정입니다. 참가자는 웹캐스트 또는 전화 회의에 등록할 수 있으며, 아카이브된 재생이 회사 웹사이트에서 제공될 것입니다.
NewAmsterdam Pharma (Nasdaq: NAMS) a annoncé qu'il publiera les données préliminaires de son essai clinique de phase 3 BROOKLYN (NCT05425745) le lundi 29 juillet 2024. L'essai évalue l'obicetrapib chez des patients atteints d'hypercholestérolémie familiale hétérozygote. NewAmsterdam, une entreprise biopharmaceutique en phase avancée, développe des médicaments oraux non-statines pour les patients à risque de maladies cardiovasculaires avec un taux élevé de LDL-C. L'entreprise organisera un webinaire en direct et une conférence téléphonique pour examiner les résultats le 29 juillet 2024 à 8h30, heure de l'Est. Les participants peuvent s'inscrire pour le webinaire ou la conférence téléphonique, et une répétition archivée sera disponible sur le site web de l'entreprise.
NewAmsterdam Pharma (Nasdaq: NAMS) hat angekündigt, dass am Montag, den 29. Juli 2024, die vorläufigen Daten aus seiner Phase-3-Studie BROOKLYN (NCT05425745) veröffentlicht werden. Die Studie bewertet Obicetrapib bei Patienten mit heterozygotem familiärem Hypercholesterinämie. NewAmsterdam, ein Unternehmen in der späten Phase der Biopharmazeutik, entwickelt orale, nicht-statinartige Medikamente für Patienten mit erhöhtem LDL-C, die ein Risiko für Herz-Kreislauf-Erkrankungen haben. Das Unternehmen veranstaltet am 29. Juli 2024 um 8:30 Uhr ET ein Live-Webcast und eine Telefonkonferenz, um die Ergebnisse zu überprüfen. Teilnehmer können sich für das Webcast oder die Telefonkonferenz anmelden, und eine archivierte Wiederholung wird auf der Website des Unternehmens verfügbar sein.
- Phase 3 clinical trial results to be announced
- Company developing non-statin medicines for cardiovascular disease patients
- None.
Company to host conference call on Monday, July 29 at 8:30 a.m. ET
NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will report topline data from the Company’s Phase 3 BROOKLYN clinical trial (NCT05425745) on Monday, July 29, 2024.
Conference Call and Webcast
NewAmsterdam will host a live webcast and conference call to review the topline results from BROOKLYN on Monday, July 29th, 2024 at 8:30 a.m. ET. To access the live webcast, participants may register here. The live webcast will be available under the "Events” section of the Investor Relations page of the NewAmsterdam website at ir.newamsterdampharma.com.
To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archived replay of the webcast will be available on NewAmsterdam’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdam
Bryan Blatstein
P: 1-917-714-2609
bblatstein@spectrumscience.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ
When will NewAmsterdam Pharma (NAMS) announce topline data from the Phase 3 BROOKLYN trial?
What is the BROOKLYN clinical trial evaluating?
When and how can investors access NewAmsterdam Pharma's (NAMS) conference call about the BROOKLYN trial results?
What type of medicines is NewAmsterdam Pharma (NAMS) developing?
